



EPS 23 x	4686972000	sobi.com	Solna, SWEDEN Inc 2001	MGMT owns --	OH -6%	LOG (Fixed)	PRICE									
47.83	EPS Rank 36				Europe Long +1.86% in 5.1 WKS											
43.48	Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haematology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden. <a href="#">LESS</a>															
39.13	<b>ANNUAL - DEC END</b>		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024 Estimate	2025 Estimate			
34.78	EPS SEK	0.23	2.86	4.08	8.57	10.78	10.52	8.67	8.52	7.47	9.66	29%	14.83	54%		
30.43	CASH FLOW/SHR SEK	1.81	1.22	4.72	7.38	11.79	16.73	17.60	14.93	13.71	<b>Earnings Growth Rate</b>		<b>Sales Growth Rate</b>			
26.09	PRETAX MARGIN %	3%	20%	24%	34%	30%	28%	21%	18%	13%	2022-24 -8% (13 Stability)		2022-24 18%			
21.74	RETURN ON EQUITY %	1%	16%	19%	31%	25%	18%	12%	11%	8%	2020-24 -6% (13 Stability)		13%			
20.00	SALES % CHANGE	24%	61%	25%	40%	56%	7%	2%	21%	18%	COMP RATING 83		SMR RATING A			
18.26	SALES (MIL) SEK	3,228	5,204	6,511	9,139	14K	15K	16K	19K	22K	INV T/O 2.2x 46					
16.52	<b>WEEKLY</b>		Aug 2	Aug 9	Aug 16	Aug 23	Aug 30	Sep 6	Sep 13	Sep 20	Sep 24	DEBT %	2021-23	39%	12%	34%
14.78	DATAGRAPH RATING	54	54	60	59	63	55	62	60	58	58	TAX RATE	2021-23	19%	21%	18%
13.04	AVG DAILY VOL (000)	310	329	334	335	349	345	351	402	394	402	BACKLOG	2021-23	--	--	--
11.30	UP/DOWN VOLUME	1.5	1.7	1.7	1.9	2.0	1.8	2.0	1.5	1.4	1.4	R & D	12.30%	BK VAL 3.19x '23		
10.43	ACCUM/DIST RATING	-16	2	33	24	33	34	38	19	19	19	DIV SEK	None	DIV GR RT--		
9.57	RELATIVE STRENGTH	60	65	81	74	77	78	82	79	79	79	BETA	0.58(7.00)	ALPHA 0.11 (0.06)		
8.26	GROUP RANK	65	54	31	35	31	37	28	21	26	26	2023 EMPLOYEES	1,772	(14%)		



<b>FINANCIALS</b>	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	P/E	50
EPS (SEK)	0.90	4.87	2.26	0.87	1.53	4.02	1.76	0.83	1.46	4.47	3.44	0.71	0.30	3.02	2.35	0.66	2.14e	4.11e	3.86e	3.18e	2024 Est.:	32.9
EPS % CHANGE	-49%	+10%	-41%	-5%	+70%	-17%	-22%	-5%	-5%	+11%	+95%	-14%	-79%	-32%	-32%	-7%	+613%e	+36%e	+64%e	+382%e	2025 Est.:	21.4
SALES (MIL SEK)	2,970.0	4,581.0	3,661.0	3,211.0	3,761.0	4,896.0	4,925.0	3,876.0	3,999.0	5,991.0	5,239.0	4,872.0	5,168.0	6,844.0	6,256.0	5,442.0	6,006.7e	7,225.6e	6,694.0e	6,298.0e	5-yr High:	47
SALES % CHANGE	+1%	-6%	-21%	+5%	+27%	+7%	+35%	+21%	+6%	+22%	+6%	+26%	+29%	+14%	+19%	+12%	+16%e	+6%e	+7%e	+16%e	5-yr Low:	11
EPS % SURPRISE	-10.6%	+15.4%	-9.5%	+39.1%	+4.3%	+23.5%	+27.8%	+15.3%	+10.1%	+6.0%	+5.9%	+39.0%	+46.7%	-15.7%	+0.3%	-13.6%					vs Ind. Avg:	
FUNDS	395	376	366	340	311	267	300	591	705	787	807	839	836	880	949	929						
SHARES HELD BY FUNDS	89M	69M	66M	58M	48M	38M	48M	62M	66M	66M	67M	66M	75M	89M	95M	96M						